Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype
Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype
复制标题
DOI：
10.1016/j.ygyno.2008.09.039
复制
发表时间：
2009-01-01
影响因子：
4.7
通讯作者：
Sakuragi, Noriaki
中科院分区：
文献类型：
--
作者：
Watari, Hidemichi;Xiong, Ying;Sakuragi, Noriaki
目标.有报道称Cyr 61在子宫内膜癌和癌细胞系中的表达较正常子宫内膜降低，并且Cyr 61的强制表达可以抑制人子宫内膜癌细胞的生长。然而，在另一份报告中，Cyr 61在所分析的大多数子宫内膜癌组织中被免疫染色。因此，本研究的目的是检测Cyr 61在子宫内膜癌中的表达，并在更大的群体中将Cyr 61表达与临床病理因素相关联。应用免疫组化和RT-PCR方法检测92例子宫内膜癌组织中Cyr 61的表达。我们将Cyr 61的表达与乳腺样腺癌患者的各种临床病理因素相关联。生存分析采用Kaplan Meier曲线和对数秩检验。多因素考克斯回归分析确定独立的预后因素。Cyr 61在92例乳腺癌中有21例（22.8%）高表达。Cyr 61的高表达与类囊腺癌患者的低生存率有关。多因素分析显示Cyr 61表达和淋巴结转移是影响生存的独立预后因素。根据Cyr 61表达和阳性LNM的组合，可以将患有类腺癌的患者的存活率分为三组，其中不考虑Cyr 61表达的无LNM的估计5年存活率为96.5%（A组），Cyr 61低/中度表达的阳性LNM的估计5年存活率为85.7%（B组），Cyr 61高表达的LNM阳性率为0%（C组）（A组vs B组p=0.18，B组vs C组p=0.008，A组vs C组p < 0.0001）。Cyr 61在某些子宫内膜癌中呈高表达。Cyr 61表达和LNM阳性是卵巢样腺癌的独立预后因素。Cyr 61可能是一个新的预测类腺癌患者预后的分子标志物。(c)2008年爱思唯尔公司All rights reserved.
Objectives. It has been reported that expression of Cyr61 decreased in endometrial cancers and cancer cell lines compared with normal endometrium, and forced expression of Cyr61 could suppress the growth of human endometrial cancer cells. However, in another report, Cyr61 was immunostained in most of endometrial cancer tissues analyzed. Thus, the aim of this study was to examine the expression of Cyr61 in endometrial cancer and to correlate Cyr61 expression with cinicopathologic factors in a larger cohort.Methods. We used immunohistochemistry and RT-PCR to examine the expression of Cyr61 in 92 endometrial carcinomas of endometrioid subtype. We correlated the expression of Cyr61 with various clinicopathologic factors in patients with endometrioid adenocarcinoma. Survival analyses were performed by the Kaplan Meier Curves and the log-rank test. Independent prognostic factors were determined by multivariate Cox regression analysis.Results. Cyr61 expression was high in 21 of 92 cases of endometrioid adenocarcinoma (22.8%). High expression of Cyr61 was related to poor survival of patients with endometrioid adenocarcinoma. Multivariate analysis including Cyr61 expression revealed that Cyr61 expression and positive lymph node metastasis (LNM) were independent prognostic factors for Survival. Survival of patients with endometrioid adenocarcinoma could be stratified into three groups by combination of Cyr61 expression and positive LNM with an estimated 5-year survival rate of 96.5% for no LNM irrespective of Cyr61 expression (group A), 85.7% for positive LNM with low/moderate expression of Cyr61 (group B), and 0% for positive LNM with high expression of Cyr61 (group C)(p=0.18 for group A vs group B, p=0.008 for group B vs group C, and p < 0.0001 for group A vs group C).Conclusions. Cyr61 is highly expressed in some endometrial cancer of endometrioid subtype. Cyr61 expression and positive LNM were independent prognostic factors for patients with endometrioid adenocarcinoma. Cyr61 might be a new molecular marker to predict the prognosis of patients with endometrioid adenocarcinoma. (c) 2008 Elsevier Inc. All rights reserved.